Yes, in most cases you can use hormone replacement therapy (HRT) and a GLP-1 medication like semaglutide or tirzepatide at the same time, and early research suggests the pairing may help midlife women lose more weight than a GLP-1 alone. GLP-1s work about as well in menopausal women as in younger ones. HRT isn't a weight-loss drug, but treating menopause symptoms and shifting hormones may make the whole plan work better. The catch is in the details, especially how your HRT is delivered, so both decisions should be made with a licensed clinician.
Key takeaways
- GLP-1s work in menopause. A 2025 analysis of the SURMOUNT tirzepatide trials found postmenopausal women lost about 23% of their body weight versus about 3% on placebo, similar to premenopausal women.
- Adding HRT may help. In a 2026 Mayo Clinic study, women on tirzepatide plus hormone therapy lost 19.2% of their weight versus 14% on tirzepatide alone, but this was an observational study, so it can't prove HRT caused the extra loss.
- Combining them is generally acceptable. The British Menopause Society says GLP-1s and HRT can be co-prescribed, with one important caveat about how the HRT is absorbed.
- Delivery route matters. GLP-1s slow digestion, which can reduce absorption of oral HRT, so transdermal (patch/gel) estrogen and a hormonal IUD or patch progestogen are often preferred.
- Both are clinician decisions. GLP-1s carry a boxed warning for thyroid C-cell tumors and other cautions; HRT has its own risks and benefits. Talk to a licensed provider.
Why is menopause weight so hard to lose?
Because your metabolism and where you store fat both change as estrogen falls. During the menopausal transition, body fat tends to redistribute toward the abdomen, the "menopause middle", and lean muscle mass declines. A contemporary review of body-composition changes across menopause links this shift to rising visceral (belly) fat and worsening insulin resistance, the same metabolic problems that make weight loss harder and cardiovascular risk higher.
Two things compound the challenge in midlife. Muscle loss speeds up around menopause, and muscle is where much of your calorie-burning happens. And this age group is the one most likely to be using GLP-1s: a 2025 RAND commentary noted that women aged 50-64 have the highest reported GLP-1 use of any group (about 20%), yet perimenopausal and menopausal women have been underrepresented in the research. The exact women reaching for these medications have the least data tailored to them, which is why an honest, women-first look at the evidence matters.
Do GLP-1s work for menopause weight gain?
Yes. The concern that these drugs "don't work as well after menopause" isn't borne out by the trial data. A 2025 analysis of 2,542 women across the SURMOUNT tirzepatide trials, published in the journal Obesity and summarized by NewYork-Presbyterian, found weight loss was comparable across reproductive stages:
| Group | Body weight lost on tirzepatide | Placebo |
|---|---|---|
| Premenopausal women | ~26% | ~2% |
| Perimenopausal women | ~23% | ~3% |
| Postmenopausal women | ~23% | ~3% |
Semaglutide shows the same pattern. In the landmark STEP 1 trial (published in The New England Journal of Medicine in 2021), adults on semaglutide 2.4 mg lost a mean of 14.9% of their body weight over 68 weeks, versus 2.4% on placebo. Individual results vary and depend on the whole program, nutrition, activity, dose, and consistency.
A naming note that matters: only Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management. Ozempic and Mounjaro contain the same molecules but are FDA-approved for type 2 diabetes, so using them for weight loss is off-label. No GLP-1 is FDA-approved specifically for menopause.
Does adding HRT help you lose more weight?
Possibly, early data point that way, but it's not proven. The most talked-about evidence is a 2026 Mayo Clinic retrospective cohort study, published in The Lancet Obstetrics, Gynaecology & Women's Health. Researchers reviewed 120 postmenopausal women who took tirzepatide for a year or more and compared those also using menopausal hormone therapy with those who weren't.
| Group (tirzepatide ≥12 months) | Average body weight lost |
|---|---|
| Tirzepatide + hormone therapy | 19.2% |
| Tirzepatide alone | 14.0% |
That's roughly 35% more weight lost, relatively speaking, in the hormone-therapy group. It's a striking finding, but read it carefully. Because this was an observational study, not a randomized trial, it can't prove hormone therapy caused the extra loss. As the study's senior author, Mayo Clinic endocrinologist Maria Daniela Hurtado Andrade, MD, PhD, put it, women using hormone therapy may have already been more engaged in healthy habits, or menopause-symptom relief may have improved their sleep and energy enough to stick with the plan. HRT is prescribed to manage menopause symptoms, it is not a weight-loss medication, so any weight benefit is a bonus being studied, not a promise.
The mechanism is plausible: by easing the estrogen-driven shift toward visceral fat and insulin resistance described above, HRT may make it easier for a GLP-1 to work and for the loss to stick. Larger randomized trials are needed to confirm it.
Is it safe to take HRT and a GLP-1 together?
Generally, yes, with attention to how your HRT is delivered. In 2025, the British Menopause Society (BMS) issued a clinician tool confirming that incretin-based therapies (the class that includes semaglutide and tirzepatide) and HRT can be used concurrently, provided the HRT formulation is chosen thoughtfully.
Here's the key issue. GLP-1s slow gastric emptying, and side effects like nausea, vomiting, and diarrhea are common, all of which can reduce how well your body absorbs an oral (swallowed) hormone. The BMS's main safety concern is endometrial protection: if oral progestogen isn't fully absorbed, the uterus may not be adequately protected against the estrogen in HRT, which raises the risk of endometrial hyperplasia. The practical fix is to favor non-oral routes:
| HRT component | Preferred with a GLP-1 | Why |
|---|---|---|
| Estrogen | Transdermal patch or gel | Bypasses the gut; also carries lower clot risk than oral estrogen in women with obesity |
| Progestogen (uterine protection) | 52 mg levonorgestrel IUD, or a combined estrogen/progestogen patch | Unaffected by slowed digestion; the IUD also provides contraception in perimenopause |
| Vaginal progesterone | Also unaffected | Not absorbed through the gut (used off-license) |
If you and your clinician choose oral progestogen anyway, the BMS suggests extra vigilance around dose. Either way, this is a coordination conversation with your menopause provider, not a DIY decision, HRT carries its own benefits and risks (including clot risk and, depending on type and duration, breast-cancer considerations) that depend on your health history.
Will it help menopausal belly fat?
It can help, but no medication targets belly fat specifically. GLP-1s reduce overall body fat, including the visceral abdominal fat that accumulates after menopause. In the SURMOUNT analysis, tirzepatide reduced not just body weight but waist circumference across all reproductive stages, a marker of that deeper belly fat. Because HRT may blunt the hormonal driver of central fat storage, the combination is being studied precisely for the "menopause middle." Just remember that "spot reduction" isn't real: you'll lose fat body-wide, with the midsection often a visible part of that.
One caveat for any midlife plan: fast weight loss can take muscle and bone with it, and menopause already accelerates both. The RAND commentary flagged lean-muscle loss as one of the most important, understudied risks for midlife women on GLP-1s, a reason to protect muscle with protein and strength training, not a reason to avoid treatment. See our guides on keeping muscle on a GLP-1 and GLP-1s and menopause weight gain.
How Elara helps
Elara is built for exactly this stage of life. Our licensed providers review every patient's full history, including where you are in the menopause transition, before deciding whether a GLP-1 is appropriate and how to start it. Elara offers branded Wegovy and Zepbound plus compounded semaglutide and compounded tirzepatide. Compounded semaglutide starts at $247/month and compounded tirzepatide at $355/month, all-inclusive (medication, provider visit, shipping, ongoing support, and the Elara app).
If you take HRT or are considering it, keep that care with your menopause specialist or gynecologist, your GLP-1 and your HRT work best when both providers know the full picture. Curious whether a lower-and-slower approach fits midlife? Read about microdosing GLP-1s in perimenopause and menopause.
Explore Elara's semaglutide program for women or compounded tirzepatide, or take a free eligibility check on our weight-loss program, a licensed provider reviews every patient.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. They are not "generic" versions of Ozempic, Wegovy, Mounjaro, or Zepbound.
Every GLP-1 also carries a boxed warning for thyroid C-cell tumors and is contraindicated if you or a close relative has had medullary thyroid carcinoma or MEN 2; other cautions include pancreatitis, gallbladder problems, and significant GI effects. GLP-1s are not recommended in pregnancy or while breastfeeding. Talk to a licensed provider about whether one is right for you.
Frequently asked questions
Can you take HRT and semaglutide or Wegovy together? In most cases, yes. The British Menopause Society confirms GLP-1s like semaglutide and hormone therapy can be used together. The main adjustment is favoring transdermal (patch or gel) estrogen and a non-oral progestogen, such as a hormonal IUD, because the medication's slowed digestion can reduce absorption of swallowed hormones. Coordinate both with your clinicians.
Do GLP-1s work for menopause weight gain? Yes. A 2025 analysis of the SURMOUNT tirzepatide trials found postmenopausal women lost about 23% of their body weight versus roughly 3% on placebo, comparable to younger women. Semaglutide shows a similar effect. The medications counter the insulin resistance and appetite changes that make midlife weight harder to lose. Individual results vary.
Does adding HRT help you lose more weight? Early research suggests it might. A 2026 Mayo Clinic study found women on tirzepatide plus hormone therapy lost 19.2% of their weight versus 14% on tirzepatide alone. But it was observational, so it can't prove HRT caused the difference. HRT is prescribed for menopause symptoms, not weight loss; any added benefit is still being studied.
Is it safe to combine HRT and a GLP-1? For most women, combining them is considered acceptable when managed by a clinician. The key safety point is uterine protection: because GLP-1s slow digestion, oral progestogen may be less reliably absorbed, so non-oral routes are preferred. HRT also has its own risks that depend on your health history, so the decision should be individualized.
Will it help menopausal belly fat? GLP-1s reduce overall body fat, including the visceral belly fat that builds up after menopause, tirzepatide lowered waist circumference in trials. HRT may ease the hormonal driver of central fat storage, which is why the combination is being studied for the "menopause middle." No medication targets belly fat alone, though; you'll lose fat body-wide.
The bottom line
For many midlife women, a GLP-1 and HRT aren't an either/or. GLP-1 medications work well after menopause, and early evidence suggests hormone therapy may enhance the results, though that finding is observational, not proof. The most important practical detail is delivery route: pairing a GLP-1 with transdermal estrogen and a non-oral progestogen keeps your HRT working while the medication does its job. Bring both decisions to licensed clinicians who can weigh your full history.
References
- NewYork-Presbyterian. "Women in Menopause Benefit From GLP-1 Weight-Loss Medications as Much as Younger Women." https://www.nyp.org/advances/article/women-in-menopause-benefit-from-glp-1-weight-loss-medications-as-much-as-younger-women
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Mayo Clinic News Network. "New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause." 2026. https://newsnetwork.mayoclinic.org/discussion/new-study-links-combination-of-hormone-therapy-and-tirzepatide-to-greater-weight-loss-after-menopause/
- "The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study." The Lancet Obstetrics, Gynaecology, & Women's Health, 2026. https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00145-1/abstract
- British Menopause Society. "Tool for Clinicians: Use of incretin-based therapies in women using HRT." April 2025. https://thebms.org.uk/wp-content/uploads/2025/05/23-BMS-TfC-Use-of-incretin-based-therapies-APRIL2025-E.pdf
- RAND Corporation. "GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities." 2025. https://www.rand.org/pubs/commentary/2025/08/glp-1-agonists-in-perimenopause-unique-risks-and-potential.html
- "Adverse Changes in Body Composition During the Menopausal Transition and Relation to Cardiovascular Risk: A Contemporary Review." National Library of Medicine (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC9258798/
- U.S. Food and Drug Administration / DailyMed (NLM). "Wegovy (semaglutide) injection, Prescribing Information" (boxed warning, thyroid C-cell tumors). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
This article is for general education and is not medical advice. It doesn't replace a conversation with a licensed clinician about your health, medications, or treatment. Reading it doesn't create a doctor-patient relationship. If you have a medical emergency, call 911. See our full Medical Disclaimer.
About compounded medications: Compounded semaglutide and tirzepatide are prepared by a state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. They are not "generic" versions of Ozempic, Wegovy, Mounjaro, or Zepbound. Talk to a licensed clinician about whether a compounded or FDA-approved option is right for you.